Peter Olagunju


Peter Olagunju is the Chief Technology Officer for TCR2. Previous to TCR2, Peter served as the SVP of Technical Operations at FerGene (a Blackstone Life Sciences backed start-up) where he worked on the commercialization of a gene therapy of bladder cancer. Previous to FerGene Peter served as the Vice President of Patient Operations with bluebird bio. In this role, Peter had responsibility for the personalized manufacturing & Centers of Excellence (COE) interfaces including the collection of patient cells, manufacture of drug product, and operational execution of patient treatments. Peter’s team de

HLTH does not sell or provide any personal data (including email, phone, address) to any third parties and we never will. Any communication that pretends to be HLTH or any third parties selling purported lists, discounted rooms, or any product/services are NOT AFFILIATED with HLTH and are to be considered FRAUD.

Upcoming Event Dates

2024 | ViVE: Feb 25-28; HLTH Europe: Jun 17-20; HLTH US: Oct 20-23

2025 | ViVE: Feb 16-19; HLTH US: Oct 19-22

2026 | HLTH US: Nov 15-18

2027 | HLTH US: Oct 17-20

© 2024 HLTH, INC. All Rights Reserved